✦ LIBER ✦

Alemtuzumab for multiple sclerosis: who and when to treat?

✍ Scribed by Till Sprenger; Ludwig Kappos

Book ID: 118553793
Publisher: The Lancet
Year: 2012
Tongue: English
Weight: 109 KB
Volume: 380
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(12)61859-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Melanoma following treatment with alemtu

Melanoma following treatment with alemtuzumab for multiple sclerosis

✍ A. A. Pace; J. P. Zajicek 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 53 KB

Genotype–phenotype correlations in tuber

Genotype–phenotype correlations in tuberous sclerosis: Who and how to treat

✍ Suzanne Goh; William A. Weiss 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB

Symptomatic and asymptomatic carotid ste

Symptomatic and asymptomatic carotid stenosis: How, when, and who to treat?

✍ Peter M. Rothwell 📂 Article 📅 2006 🏛 Current Science Inc. 🌐 English ⚖ 237 KB

Bisphosphonate therapy for patients with

Bisphosphonate therapy for patients with breast carcinoma : Who to treat and when to stop

✍ Timothy A. Plunkett; Robert D. Rubens 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB

Bisphosphonates have become well established in the treatment of patients with metastatic bone disease, although the optimal use of these agents has not been defined clearly. Randomized, controlled trials have demonstrated that treatment with intravenous pamidronate can significantly reduce the rate

Fulfilling the dream: tolerogenic dendri

Fulfilling the dream: tolerogenic dendritic cells to treat multiple sclerosis

✍ Catharina C. Gross; Helmut Jonuleit; Heinz Wiendl 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 570 KB

Fingolimod (FTY720): discovery and devel

Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis

✍ Brinkmann, Volker; Billich, Andreas; Baumruker, Thomas; Heining, Peter; Schmoude 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 96 KB